Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Heron Therapeutics Inc

HRTX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.36

▼ -6.79%

Market Cap $68.01M · Vol 813.99K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$68.01M

Micro Cap

Div Yield

N/A

EPS Growth

-164.00%

YoY

RSI (14)

58.19

Momentum

Beta

1.66

vs Market

52W High

$1.58

77.26% below

52W Low

$0.26

37.19% above

Volume

813.99K

Avg 413.84K

P/B

18.43

Price-to-book

ROE

N/A

Return on equity

Free Float

97.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Heron Therapeutics Inc (HRTX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HRTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.65%

+2.34%

-19.60%

-56.95%

YTD

-72.45%

-73.47%

-59.76%

-96.46%

Financials & Valuation

TTM · Annual

Total Revenue	$154.90M
Net Income	$-20,195,000.00
Revenue Growth (YoY)	+1.25%
Gross Margin	73.31%
Operating Margin	-1.64%
Net Profit Margin	-13.04%
ROE	N/A
ROA · ROIC	-8.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.40
P/B	18.43
P/FCF	N/A
EPS Growth	-164.00%
Outstanding Shares	189.85M

Technical Indicators

50-Day SMA	$0.35
200-Day SMA	$0.78
RSI (14)	58.19
Beta	1.66
52-Week High	$1.58
52-Week Low	$0.26

Volume Today	813.99K
Avg Daily Volume (30D)	413.84K
Relative Volume	1.97x
Volatility (10D)	120.16
Volatility (30D)	93.95
Free Float	97.69%

Analyst Consensus

HOLD

Current Price $0.36

Mean Target N/A

52W Low$0.26 52W High$1.58

Current

Target

$0.26 $1.58

Current Analyst target

· 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SB92D4

ISINUS4277461020

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -4.30% ARGX.BR argenx SE -15.86% ARGX argenx SE -11.83% 2269.HK WuXi Biologics (Cayman) Inc. -4.59% GMAB Genmab A/S -1.64%

Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.